Search

Your search keyword '"Potts, Kyle G."' showing total 16 results
Start Over Author "Potts, Kyle G."
16 results on '"Potts, Kyle G."'

1. VSV∆M51 drives CD8+ T cell-mediated tumour regression through infection of both cancer and non-cancer cells

Author

Rajwani, Jahanara, Vishnevskiy, Daniil, Turk, Madison, Naumenko, Victor, Gafuik, Chris, Kim, Dae-Sun, Mah, Laura K., Snelling, Shannon, Gonzales, Gerone A., Xue, Jingna, Chanda, Ayan, Potts, Kyle G., Todesco, Hayley M., Lau, Keith C. K., Hildebrand, Karys M., Chan, Jennifer A., Liao, Shan, Monument, Michael J., Hyrcza, Martin, Bose, Pinaki, Jenne, Craig N., Canton, Johnathan, Zemp, Franz J., and Mahoney, Douglas J.

Published
2024
Full Text
View/download PDF

4. A B1a–natural IgG–neutrophil axis is impaired in viral- and steroid-associated aspergillosis

Author

Sarden, Nicole, primary, Sinha, Sarthak, additional, Potts, Kyle G., additional, Pernet, Erwan, additional, Hiroki, Carlos H., additional, Hassanabad, Mortaza F., additional, Nguyen, Angela P., additional, Lou, Yuefei, additional, Farias, Raquel, additional, Winston, Brent W., additional, Bromley, Amy, additional, Snarr, Brendan D., additional, Zucoloto, Amanda Z., additional, Andonegui, Graciela, additional, Muruve, Daniel A., additional, McDonald, Braedon, additional, Sheppard, Donald C., additional, Mahoney, Douglas J., additional, Divangahi, Maziar, additional, Rosin, Nicole, additional, Biernaskie, Jeff, additional, and Yipp, Bryan G., additional

Published
2022
Full Text
View/download PDF

6. Identification of FDA-approved bifonazole as a SARS-CoV-2 blocking agent following a bioreporter drug screen

Author

Taha, Zaid, primary, Arulanandam, Rozanne, additional, Maznyi, Glib, additional, Godbout, Elena, additional, Carter-Timofte, Madalina E., additional, Kurmasheva, Naziia, additional, Reinert, Line S., additional, Chen, Andrew, additional, Crupi, Mathieu J.F., additional, Boulton, Stephen, additional, Laroche, Geneviève, additional, Phan, Alexandra, additional, Rezaei, Reza, additional, Alluqmani, Nouf, additional, Jirovec, Anna, additional, Acal, Alexandra, additional, Fekete, Emily E.F., additional, Singaravelu, Ragunath, additional, Petryk, Julia, additional, Idorn, Manja, additional, Potts, Kyle G., additional, Todesco, Hayley, additional, John, Cini, additional, Mahoney, Douglas J., additional, Ilkow, Carolina S., additional, Giguère, Patrick, additional, Alain, Tommy, additional, Côté, Marceline, additional, Paludan, Søren R., additional, Olagnier, David, additional, Bell, John C., additional, Azad, Taha, additional, and Diallo, Jean-Simon, additional

Published
2022
Full Text
View/download PDF

11. Procaspase-activating compound-1 synergizes with trail to induce apoptosis in established granulosa cell tumor cell line (Kgn) and explanted patient granulosa cell tumor cells in vitro

Author

Crosley, Powel, Farkkila, Anniina, Jenner, Adrianne L., Burlot, Chloé, Cardinal, Olivia, Potts, Kyle G., Agopsowicz, Kate, Pihlajoki, Marjut, Heikinheimo, Markku, Craig, Morgan, Fu, Yangxin, Hitt, Mary M., Crosley, Powel, Farkkila, Anniina, Jenner, Adrianne L., Burlot, Chloé, Cardinal, Olivia, Potts, Kyle G., Agopsowicz, Kate, Pihlajoki, Marjut, Heikinheimo, Markku, Craig, Morgan, Fu, Yangxin, and Hitt, Mary M.

Abstract

Granulosa cell tumors (GCT) constitute only ~5% of ovarian neoplasms yet have significant consequences, as up to 80% of women with recurrent GCT will die of the disease. This study investigated the effectiveness of procaspase-activating compound 1 (PAC-1), an activator of procaspase-3, in treating adult GCT (AGCT) in combination with selected apoptosis-inducing agents. Sensitivity of the AGCT cell line KGN to these drugs, alone or in combination with PAC-1, was tested using a viability assay. Our results show a wide range in cytotoxic activity among the agents tested. Synergy with PAC-1 was most pronounced, both empirically and by mathematical modelling, when combined with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). This combination showed rapid kinetics of apoptosis induction as determined by caspase-3 activity, and strongly synergistic killing of both KGN as well as patient samples of primary and recurrent AGCT. We have demonstrated that the novel combination of two pro-apoptotic agents, TRAIL and PAC-1, significantly amplified the induction of apoptosis in AGCT cells, warranting further investigation of this combination as a potential therapy for AGCT.

Published
2021

12. Stroke-associated intergenic variants modulate a human FOXF2 transcriptional enhancer.

Author

Jae-Ryeon Ryu, Ahuja, Suchit, Arnold, Corey R., Potts, Kyle G., Mishra, Aniket, Qiong Yang, Sargurupremraj, Muralidharan, Mahoney, Douglas J., Seshadri, Sudha, Debette, Stéphanie, and Childs, Sarah J.

Subjects
FORKHEAD transcription factors, BINDING sites, GENE expression, ISCHEMIC stroke, WHITE matter (Nerve tissue)
Abstract

SNPs associated with human stroke risk have been identified in the intergenic region between Forkhead family transcription factors FOXF2 and FOXQ1, but we lack amechanism for the association. FoxF2 is expressed in vascular mural pericytes and is important for maintaining pericyte number and stabilizing small vessels in zebrafish. The stroke-associated SNPs are located in a previously unknown transcriptional enhancer for FOXF2, functional in human cells and zebrafish. We identify critical enhancer regions for FOXF2 gene expression, including binding sites occupied by transcription factors ETS1, RBPJ, and CTCF. rs74564934, a stroke-associated SNP adjacent to the ETS1 binding site, decreases enhancer function, as does mutation of RPBJ sites. rs74564934 is significantly associated with the increased risk of any stroke, ischemic stroke, small vessel stroke, and elevated white matter hyperintensity burden in humans. Foxf2 has a conserved function cross-species and is expressed in vascular mural pericytes of the vessel wall. Thus, stroke-associated SNPs modulate enhancer activity and expression of a regulator of vascular stabilization, FOXF2, thereby modulating stroke risk. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

13. Procaspase-Activating Compound-1 Synergizes with TRAIL to Induce Apoptosis in Established Granulosa Cell Tumor Cell Line (KGN) and Explanted Patient Granulosa Cell Tumor Cells In Vitro

Author

Crosley, Powel, primary, Farkkila, Anniina, additional, Jenner, Adrianne L., additional, Burlot, Chloé, additional, Cardinal, Olivia, additional, Potts, Kyle G., additional, Agopsowicz, Kate, additional, Pihlajoki, Marjut, additional, Heikinheimo, Markku, additional, Craig, Morgan, additional, Fu, Yangxin, additional, and Hitt, Mary M., additional

Published
2021
Full Text
View/download PDF

15. Oncolytic Viruses in the Treatment of Bladder Cancer

Author

Potts, Kyle G., Hitt, Mary M., and Moore, Ronald B.

Subjects
Article Subject, urologic and male genital diseases
Abstract

Bladder carcinoma is the second most common malignancy of the urinary tract. Up to 85% of patients with bladder cancer are diagnosed with a tumor that is limited to the bladder mucosa (Ta, T1, and CIS). These stages are commonly termed as non-muscle-invasive bladder cancer (NMIBC). Although the treatment of NMIBC has greatly improved in recent years, there is a need for additional therapies when patients fail bacillus Calmette-Guérin (BCG) and chemotherapeutic agents. We propose that bladder cancer may be an ideal target for oncolytic viruses engineered to selectively replicate in and lyse tumor cells leaving normal cells unharmed. In support of this hypothesis, here we review current treatment strategies for bladder cancer and their shortcomings, as well as recent advancements in oncolytic viral therapy demonstrating encouraging safety profiles and antitumor activity.

Published
2012
Full Text
View/download PDF

16. Assessment of Specificity of an Adenovirus Targeted to HER3/4.

Author

MacLeod SH, Potts KG, Chaurasiya S, and Hitt MM

Subjects
Animals, CHO Cells, Cricetulus, Fluorescent Antibody Technique, Gene Expression, Gene Transfer Techniques, Genes, Reporter, Humans, Microscopy, Confocal, Transduction, Genetic, Transgenes, Adenoviridae genetics, Gene Targeting methods, Genetic Vectors genetics, Receptor, ErbB-3 genetics, Receptor, ErbB-4 genetics
Abstract

Gene therapy with viral vectors, such as adenovirus (Ad), targeted to the human epidermal growth factor receptors 3 and 4 (HER3/4) are potentially useful for cancer therapy. Testing the expression of a reporter gene from these viruses in target cells is essential to determine functionality of the targeted virus. A competition assay with a relevant ligand (heregulin, HRG) can provide convincing evidence that blocking binding to the HER3/4 receptor results in decreased reporter gene expression. Labeling individual viruses with a fluorescent molecule allows examination of the targeted virus in specific steps in the infection. Virus internalization into cell lines can be determined using antibody-labeled receptors, and the virus colocalization with receptors can also be visualized. Characterization of a targeted virus in this fashion is important to demonstrate that the targeting of the virus functions in an expected manner, and provides support for larger-scale testing of the virus. Information acquired in these experiments may also be useful to inform and improve on the design of future targeted viruses.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results